These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647 [TBL] [Abstract][Full Text] [Related]
4. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Togashi Y; Hayashi H; Nakagawa K; Nishio K Drug Des Devel Ther; 2014; 8():1037-46. PubMed ID: 25114510 [TBL] [Abstract][Full Text] [Related]
5. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Murphy M; Stordal B Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938 [TBL] [Abstract][Full Text] [Related]
6. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Jotte RM; Spigel DR Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719 [TBL] [Abstract][Full Text] [Related]
7. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518 [TBL] [Abstract][Full Text] [Related]
8. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer. Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995 [TBL] [Abstract][Full Text] [Related]
10. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Nguyen KS; Kobayashi S; Costa DB Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948 [TBL] [Abstract][Full Text] [Related]
13. [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs]. Wang Y; Liu H; Chen J Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):375-9. PubMed ID: 20677568 [TBL] [Abstract][Full Text] [Related]
14. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Sohn HS; Kwon JW; Shin S; Kim HS; Kim H J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867 [TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
16. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152 [TBL] [Abstract][Full Text] [Related]